CURE Pharmaceutical Announces $20 Million Sale of a Portion of its Platform Technology IP and Related Assets

Stradling represented CURE Pharmaceutical, a biopharmaceutical company focusing on the development and manufacturing of drug formulation and drug delivery technologies, in the $20 million sale of a portion of its platform technology intellectual property and related assets.

Read the full press release here.